Axogen, Inc. (AXGN) analyst actions
Rating and price-target actions on AXGN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the AXGN overview →
3 measured AXGN analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Axogen, Inc. (AXGN) And Encourages Shareholders to Reach Out | Press release | +0.80% | +2.09% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Axogen, Inc. (AXGN) And Encourages Stockholders to Reach Out | Press release | +0.19% | -1.54% | |
| Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft® | Press release | -0.50% | -1.32% |
Keep exploring
More AXGN: earnings → · SEC filings → · AXGN overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Bruker Corporation (BRKR) | 395 | -0.10% | 46% |
| Neuronetics, Inc. (STIM) | 395 | -0.21% | 45% |
| Fulgent Genetics, Inc. (FLGT) | 393 | +0.04% | 51% |
| Kazia Therapeutics Limited - American Depositary Shares (KZIA) | 393 | -1.07% | 34% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.